Baltic Countries

New Baltic collaboration

08.09.2010

Riga – According to an announcement following a meeting of senior staff in mid-August, JCS Grindeks will collaborate in product development with the Latvian Institute of Organic Synthesis (IOS). The collaboration will involve the chemists in a clinical programme in China and “various patent-protected and generic products.” Net profit of the country’s largest drugmaker in Q2/2010 was up 20.6%, while turnover rose by 7.7% compared with the first six months of 2009. The Group’s gross profit margin in the first half of 2010 was 56.4%, while net profit hit 12.8%. The main export markets for Grindeks’ APIs were Europe, Japan, the US, Australia, Pakistan and India.

Baltic Countries

13.05.2010

Riga – Latvian producer of active pharmaceuticals ingredients Grindeks has baggedEUR4.1m in funding from the European Regional Development Fund to build a new 1,400 m2 plant for the production of ursodeoxycholic acid (UDCA). The...

Baltic Countries

12.05.2010

Kaunas/Martin – Lithuania’s largest pharmaceutical manufacturer Sanitas AB transferred its ownership in Slovakia’s HBM Pharma sro to the Lat­vian company SIA Liplats 2000 at the end of April. The companies have agreed to transfer...

Baltic Countries

18.08.2008

Riga – Starting in June, Lithuanian researchers involved in FP7 funding projects have the possibility to receive national co-funding if the EU funding programme does not cover 100% of the project cost. Additionally, a new grant...

Baltic Countries

20.05.2008

Riga – Pharmaceutical manufacturer Grindeks is continuing to expand. After opening a representative office in Uzbekistan, the company has now signed an agreement with Wake Forest University’s School of Medicine (US) to supply...

Baltic Countries

19.03.2008

Riga – The Latvian Government will be funding a EUR6 million vaccination programme over the next three years. The programme will cover vaccinations against tuberculosis, hepatitis B, tetanus, tick encephalitis, influenza, polio,...

Baltic Countries

19.02.2008

Vilnius/Brussels – For the first time, the European Commission has taken a member state of the European Union to the European Court of Justice because it refuses to take a biosimilar from the market. Lithuania has refused to...

Baltic Countries

22.11.2007

Riga – Latvia’s largest pharmaceutical manufacturer, JSC Grindeks, has signed a letter of intent (LOI) with two pharmaceutical companies in Belarus during the third meeting of the “Latvian-Byelorussian Inter-Governmental...

Baltic Countries

24.09.2007

Riga – JSC Grindeks has improved its half-year result in 2007. In the first six months of this year, the company‘s revenues grew by 25% to €37.1 million. Half of Grindeks made most sales in Russia (€18.8 million, +8%), and other...

Baltic Countries

11.07.2007

Kaunas – Sanitas AB group net profits have risen by almost seven times (598%) to a6.2 million in the first quarter of 2007 compared to last year, the Lithuanian pharmaceutical manufacturer reported at the end of May. Turnover...

Baltic Countries

11.07.2007

Riga – In mid June, LSC Grindeks unveiled a new a4.5 million cGMP and GLP compliant laboratory for scale-up procedures and industrial analytics – the only lab of this kind in the Baltic States, says the company. “The development...

Displaying results 11 to 20 out of 58

< Previous 11-20 Next >

© 2007-2015 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-baltic-countries/browse/1/article/new-baltic-collaboration.html

Product of the week

Products

Events

All Events

Stock list

All quotes

TOP

  • FORMYCON13.90 EUR12.10%
  • MAGFORCE5.10 EUR7.82%
  • SANTHERA103.00 CHF5.64%

FLOP

  • CYTOS0.32 CHF-17.95%
  • CO.DON2.15 EUR-4.44%
  • MEDIGENE3.80 EUR-4.28%

TOP

  • ADDEX3.44 CHF47.6%
  • CYTOS0.32 CHF45.5%
  • FORMYCON13.90 EUR39.1%

FLOP

  • ACTELION100.70 CHF-15.1%
  • MOLOGEN5.72 EUR-13.7%
  • BIOFRONTERA2.02 EUR-12.2%

TOP

  • SANTHERA103.00 CHF2494.5%
  • BB BIOTECH248.45 EUR96.5%
  • FORMYCON13.90 EUR80.5%

FLOP

  • CYTOS0.32 CHF-90.3%
  • 4SC0.82 EUR-50.9%
  • MOLOGEN5.72 EUR-50.8%

No liability assumed, Date: 27.01.2015

Current issue

All issues